The Coxsackie-IgG Type B1 (IFT) test looks for long-term (IgG) antibodies against Coxsackievirus B1, part of the enterovirus family. It is performed by indirect immunofluorescence (IFT) and may be reported qualitatively (positive/negative) or semi-quantitatively (index/titer). IgG reflects past exposure and immune memory and does not by itself confirm an active infection. Because enteroviruses can cross-react serologically and IFT cutoffs vary by lab, interpretation depends on clinical context, the precise titer/index, and whether there is a rising titer on paired samples. If you are evaluating a current illness, IgG alone can’t time the infection; consider PCR/NAAT from appropriate sites (e.g., throat or nasopharyngeal swab, stool, CSF, or lesion swab) and, when feasible, acute and convalescent sera—a fourfold rise in IgG over 2–4 weeks supports recent infection. Coxsackie B viruses have been associated with aseptic meningitis, pleurodynia, myopericarditis, and occasionally pancreatic involvement; if you have chest pain, shortness of breath, or concerning systemic symptoms, discuss ECG, troponin, echocardiogram, and standard labs with your clinician. In asymptomatic people, an isolated positive/elevated IgG typically indicates past exposure and requires no specific treatment. Management for suspected acute enterovirus disease is usually supportive, with targeted care based on complications. Always use the performing lab’s reference ranges and interpret alongside symptoms and other test results.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.